Zymeworks Inc.
NASDAQ: ZYME0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kenneth H. Galbraith
- Employees
- 299
- Headquarters
- Middletown, Canada
- IPO year
- 2017
- Market cap
- $1.8B
- Website
- https://www.zymeworks.com
Loading ZYME…
Loading profile data…Frequently asked questions about ZYME
What does Zymeworks Inc. (ZYME) do?
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for v...
Where does ZYME trade?
Zymeworks Inc. (ZYME) trades on the NASDAQ Global Select.
What sector is ZYME in?
Zymeworks Inc. (ZYME) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zymeworks Inc.?
Kenneth H. Galbraith is the chief executive officer of Zymeworks Inc. (ZYME).
Where is Zymeworks Inc. headquartered?
Zymeworks Inc. is headquartered in Canada.
Does ZYME pay a dividend?
Zymeworks Inc. (ZYME) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZYME go public?
Zymeworks Inc. (ZYME) completed its initial public offering in 2017.